BCYC News and Press, Bicycle Therapeutics plc From 05/09/24

2024-05-09 10:38:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-05-02 13:54:52 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Bicycle Therapeutics (NASDAQ: BCYC ) just reported results for the first quarter of 2024. Bicycle Therapeutics reported earnings per share of -62 cents. This was above the...

2024-05-02 07:56:32 ET More on Bicycle Therapeutics Bicycle: 2nd Half Of 2024 Data Could Provide Significant Inflection Point Cantor sees strong year ahead for oncology M&A Bicycle Therapeutics gains as former Seagen holder boosts stake Seeking Alpha ...

Resideo Technologies Inc. (REZI) is expected to report $0.33 for Q1 2024 Schneider National Inc. (SNDR) is expected to report $0.13 for Q1 2024 Murphy Oil Corporation (MUR) is expected to report $0.82 for Q1 2024 Astronics Corp. - Class B (ATROB) is expected to report for Q1 2024 ...

Multiple preclinical and clinical abstracts accepted for presentation at 2024 ASCO Annual Meeting and AACR Annual Meeting underscore breadth of Bicycle ® platform technology and pipeline Continued progress across research and development (R&D) pipeline, with numerous clinical...

Bicycle Therapeutics plc (NASDAQ: BCYC), a biopharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle ® ) technology, today announced the acceptance of two abstracts for poster presentation at the 2024 Amer...

2024-04-03 07:26:26 ET More on Homology Medicines Financial information for Homology Medicines Read the full article on Seeking Alpha For further details see: Q32 Bio names Lee Kalowski as CFO

Bicycle Therapeutics plc (NASDAQ: BCYC), a biopharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle ® ) technology, today announced that management will participate in a fireside chat at the 23rd Annual N...

2024-03-25 13:07:32 ET Summary M&A activity in the biotech/biopharma sector is expected to remain active due to significant cash on Big Pharma's balance sheets, key patent expirations, and declining revenue from Covid related products. The oncology space continues to be a hot ...

2024-03-19 08:19:47 ET More on Fusion Pharmaceuticals Fusion Pharmaceuticals' Partnerships Strengthen Long-Term Outlook Biggest stock movers today: FUSN, NCMI, crypto stocks and more AstraZeneca will buy Fusion Pharmaceuticals for ~$2B Seeking Alpha’s ...